Clarifying the PSA grey zone: The management of patients with a borderline PSA.

about

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis.

P2860

Q55020746-FC8E1C17-ECC4-42D6-B3BA-8947693EB7B5

P2860

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

Item

http://www.wikidata.org/entity/Q38965360

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

@en

type

Item

label

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

@en

prefLabel

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

@en

P1476

Clarifying the PSA grey zone: The management of patients with a borderline PSA

@en

P2093

Kamran Ahmed

http://www.w3.org/2001/XMLSchema#string

Nicholas Raison

http://www.w3.org/2001/XMLSchema#string

P2860

Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer

The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists

The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

P304

950-959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12883

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Prokar Dasgupta

Benjamin Challacombe

Talisa Ross

P577

2016-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27672001

http://www.w3.org/2001/XMLSchema#string

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

about

P2860

P2860

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698